Annual Report 2008 Q-Med AB (publ)

Annual Report 2008 Q-Med AB (publ)

Q-Med's Annual Report can be downloaded from the company's website at 
www.q-med.com as from today.

The Annual Report will be sent to Q-Med shareholders who have actively requested
this and to other stakeholders during the week commencing April 13.

Queries should be addressed to:
Kristin Ermanbriks, Manager Corporate Administration
Tel: +46 (0) 70 974 9071

Q-Med AB is a rapidly growing and profitable medical device company. The company
develops, manufactures, markets, and sells primarily medical implants. The
majority of the products are based on the company's patented technology, NASHA™,
for the production of stabilized non-animal hyaluronic acid. The product
portfolio today contains: Restylane® for filling lines and folds, contouring and
creating volume in the face, Macrolane™ for body contouring, Durolane™ for the
treatment of osteoarthritis of the hip and knee joints, Deflux® for the
treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder)
in children, and Solesta™ for the treatment of fecal incontinence. Sales are
made through the company's own subsidiaries or distributors in over 70
countries. Q Med today has just over 650 coworkers, with approximately 400 at
the company's head office and production facility in Uppsala, Sweden. Q-Med AB
is listed in the Mid Cap segment of the NASDAQ OMX Nordic. 


Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q-med.com. Web:
www.q-med.com.

In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia,
Inc.